The Shareholders’ Meeting for Reporting Completion of the Merger

SCAI Therapeutics Co., Ltd. (hereinafter referred to as the “Company”) hereby announces that, pursuant to the merger agreement executed on November 1, 2024, and in accordance with the provisions of Article 527-3 of the Korean Commercial Act, the Board of Directors, in lieu of a shareholders’ meeting, resolved that the Company would absorb A-STIN Co., Ltd. (“A-STIN”), succeeding to all of A-STIN’s rights and obligations, and that A-STIN would be dissolved.

Both companies have completed all procedures required under the Korean Commercial Act.
In accordance with Article 526, Paragraph 3 of the Korean Commercial Act, the Board of Directors has resolved that the shareholders’ meeting for reporting the completion of the merger shall be replaced by this public notice. Accordingly, the completion of the merger is hereby reported to all shareholders as follows.

Details of the Merger

1. Parties to the Merger
   a. Surviving Company:
   SCAI Therapeutics Co., Ltd.
   (2F, 21, Gangnam-daero 107-gil, Seocho-gu, Seoul, Republic of Korea, Daeneung Building, Jamwon-dong)

   b. Dissolved Company:
   A-STIN Co., Ltd.
   (2F, 167-6, Techno 2-ro, Yuseong-gu, Daejeon, Republic of Korea)

2. Merger Ratio: 1 : 10

3. New Shares Issued for the Merger: 90,050 common shares

4. Change in Total Number of Authorized Shares:
   The total number of authorized shares under the Articles of Incorporation of SCAI Therapeutics Co., Ltd. remains unchanged as a result of the merger.

5. Change in Capital:
   As a result of the merger, the capital of SCAI Therapeutics Co., Ltd. has increased by KRW 45,025,000, bringing the total paid-in capital to KRW 599,795,500 immediately after the registration of the merger.

6. Merger Process:
   Please refer to the attached file for detailed progress of the merger.

January 2, 2025
SCAI Therapeutics Co., Ltd.
Chief Executive Officer: Chul hwan Kim